A ligand-based and docking-based virtual screening was carried out to identify novel MDM2 inhibitors. A pharmacophore model with four features was used for virtual screening, followed by molecular docking. Seventeen compounds were selected for an in vitro MDM2 inhibition assay, and compounds AO-476/43250177, AG-690/37072075, AK-968/15254441, AO-022/43452814, and AF-399/25108021 showed promising MDM2 inhibition activities with values of 9.5, 8.5, 23.4, 3.2, and 23.1 μM, respectively. Four compounds also showed antiproliferative activity, and compound AO-022/43452814 was the most potent hit with IC50 values of 19.35, 26.73, 12.63, and 24.14 μM against MCF7 (p53 +/+), MCF7 (p53 -/-), HCT116 (p53 +/+), and HCT116 (p53 -/-) cell lines, respectively. Compound AO-022/43452814 could be used as a scaffold for the development of anticancer agents targeting MDM2.
A series of novel indolone derivatives were synthesized and evaluated for their binding affinities toward MDM2 and MDMX. Some compounds showed potent MDM2 and moderate MDMX activities. Among them, compound A13 exhibited the most potent affinity toward MDM2 and MDMX, with a Ki of 0.031 and 7.24 μM, respectively. A13 was also the most potent agent against HCT116, MCF7, and A549, with IC50 values of 6.17, 11.21, and 12.49 μM, respectively. Western blot analysis confirmed that A13 upregulated the expression of MDM2, MDMX, and p53 by Western blot analysis. These results indicate that A13 is a potent dual p53-MDM2 and p53-MDMX inhibitor and deserves further investigation.
A series of novel piperidamide-3-carboxamide derivatives were synthesized and evaluated for their inhibitory activities against cathepsin K. Among these derivatives, compound H-9 exhibited the most potent inhibition, with an IC50 value of 0.08 µM. Molecular docking studies revealed that H-9 formed several hydrogen bonds and hydrophobic interactions with key active-site residues of cathepsin K. In vitro, H-9 demonstrated anti-bone resorption effects that were comparable to those of MIV-711, a cathepsin K inhibitor currently in phase 2a clinical trials for the treatment of bone metabolic disease. Western blot analysis confirmed that H-9 effectively downregulated cathepsin K expression in RANKL-reduced RAW264.7 cells. Moreover, in vivo experiments showed that H-9 increased the bone mineral density of OVX-induced osteoporosis mice. These results suggest that H-9 is a potent anti-bone resorption agent targeting cathepsin K and warrants further investigation for its potential anti-osteoporosis values.
Cathepsin K (Cat K) is a promising therapeutic target for osteoporosis due to its essential role in osteoclast-mediated bone resorption. A series of novel benzylindole derivatives were designed, synthesized, and evaluated as Cat K inhibitors through structure–activity relationship (SAR) exploration. Among three classes of compounds (A–C), the sulfonate ester derivatives (C-series) exhibited substantially improved potency. Compound C5 emerged as the most active analog, with an IC50 of 0.04 μM against Cat K. Molecular docking revealed that C5 forms dual hydrogen bonds with Cys25, together with extensive hydrophobic interactions. In cellular assays, C5 effectively reduced CTX-I release (18.27 ± 2.27 nM) and bone resorption pit formation in RANKL-stimulated RAW264.7 osteoclasts. Western blot analysis confirmed that C5 downregulated Cat K protein expression. In an ovariectomized (OVX) mouse model of osteoporosis, oral administration of C5 at 80 mg/kg significantly restored bone mineral density (BMD) to 0.26 ± 0.02 g/cm2. Collectively, these findings identify compound C5 as a promising lead candidate for further development as a novel anti-osteoporotic agent targeting Cat K.